Diagnosis and Management of Acute Leukemia(AML, ALL): Drafting from Molecular Mechanisms to Clinical Practice

A special issue of Hematology Reports (ISSN 2038-8330).

Deadline for manuscript submissions: closed (7 March 2024) | Viewed by 872

Special Issue Editors

Department of Biomed & Prevent, University of Rome Tor Vergata, Rome, Italy
Interests: acute leukemia; measurable residual disease; myelodysplastic syndromes; bone marrow transplant
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, 47014 Meldola, Italy
Interests: acute lymphoblastic leukemia; acute myeloid leukemia; myelodysplastic syndromes; multiple myeloma and MGUS; non-Hodgkin and Hodgkin lymphoma
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Thanks to crucial advances in the understanding of leukemias’ biology, we are approaching a new era in the management of these challenging diseases. Accordingly, deciphering the mechanisms of leukemogenesis is no more limited to descriptive purposes but extends to clinical implications. Ever new molecular pathways involved in promoting and maintaining leukemogenesis at different levels are being discovered, possibly paving the way to innovative therapeutic approaches. Delivering targeted treatment to patients with specific molecular subtypes will hopefully represent an opportunity to abandon the old “to treat or not to treat” paradigm in favour of a more appropriate “how to best treat” approach.

In the present Special Issue, we will discuss how the understanding of Acute Leukemias biology is expected to change the treatment paradigm both in pediatric and adult patients, hopefully revolutionising the therapeutic approach to such “hard-to-treat” malignancies.

Dr. Raffaele Palmieri
Dr. Claudio Cerchione
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Hematology Reports is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • acute myeloid leukemia
  • acute lymphoid leukemia
  • cancer biology
  • novel therapeutics
  • measurable residual disease

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

8 pages, 987 KiB  
Case Report
Successful Bone Marrow Transplantation in a Patient with Acute Myeloid Leukemia Developed from Severe Congenital Neutropenia Using Modified Chemotherapy and Conditioning Regimen for Leukemia
by Risa Matsumura, Shinji Mochizuki, Yusuke Morishita, Hiroko Hayakawa, Shuhei Karakawa, Hiroshi Kawaguchi, Satoshi Okada, Nobuyuki Hyakuna and Masao Kobayashi
Hematol. Rep. 2024, 16(1), 98-105; https://doi.org/10.3390/hematolrep16010010 - 26 Feb 2024
Viewed by 508
Abstract
Severe congenital neutropenia (SCN) is characterized by chronic neutropenia with recurrent infections from early infancy and a predisposition to myelodysplastic syndrome/acute myeloid leukemia (AML). Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative treatment for patients with SCN who develop myelodysplastic syndrome/AML. [...] Read more.
Severe congenital neutropenia (SCN) is characterized by chronic neutropenia with recurrent infections from early infancy and a predisposition to myelodysplastic syndrome/acute myeloid leukemia (AML). Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative treatment for patients with SCN who develop myelodysplastic syndrome/AML. We report an 8-year-old girl with SCN carrying an ELANE mutation that had been refractory to granulocyte colony-stimulating factor. The patient experienced recurrent infections and then developed AML. The counts of leukemic blasts that harbored both CSF3R and RUNX1 mutations spontaneously decreased with antimicrobial therapy, leading to partial remission. After AML recurrence, HSCT was successfully performed using modified chemotherapy and a conditioning regimen. Serial donor lymphocyte infusions against mixed chimerism induced complete donor chimerism over 4 years without any infections or AML relapse. This case suggests the importance of carefully managing neutropenia-related infections, leukemia progression, and HSCT in patients with SCN developing AML. Full article
Show Figures

Figure 1

Back to TopTop